2011
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients
Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 2011, 80: 978-985. PMID: 21775975, PMCID: PMC3656595, DOI: 10.1038/ki.2011.228.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCardiovascular DiseasesDrug Therapy, CombinationFemaleHumansHypertensionKaplan-Meier EstimateKidney Failure, ChronicLogistic ModelsMaleMiddle AgedPropensity ScoreProportional Hazards ModelsRenal DialysisRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesConceptsAngiotensin receptor blockersAntihypertensive medicationsARB therapyCardiovascular deathChronic hemodialysisCardiovascular mortalityHazard ratioHemodialysis patientsRisk factorsBaseline cardiovascular risk factorsAngiotensin-converting enzyme inhibitionLarge dialysis providerCardiovascular risk factorsChronic hemodialysis patientsKaplan-Meier methodMortality hazard ratioAntihypertensive therapyReceptor blockersAntihypertensive agentsCox regressionCerebrovascular mortalityClinical trialsTreatment weightingObservational studyACEI
1999
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein R, O’Neill J, Holcomb G, Morgan W, Neblett W, Oates J, Brown N, Nadeau J, Smith B, Page D, Abumrad N, Scott H. Clinical Experience Over 48 Years With Pheochromocytoma. Annals Of Surgery 1999, 229: 755. PMID: 10363888, PMCID: PMC1420821, DOI: 10.1097/00000658-199906000-00001.Peer-Reviewed Original ResearchConceptsMicroscopic malignant featuresExtraadrenal pheochromocytomaMalignant diseaseMalignant featuresAdrenal pheochromocytomaSurgical managementMultiple endocrine neoplasia type 2Von Hippel-Lindau diseasePatient's malignant diseaseSame overall survivalLong-term outcomesRate of malignancyKaplan-Meier survival distributionsNumber of patientsVon Recklinghausen's diseaseHippel-Lindau diseaseAreas of controversyCarney syndromeAdrenal tumorsOverall survivalMale patientsFemale patientsBenign diseasePatient survivalFormer tumor